Home
Stampa
Auditorium Orange 1 Spalato Pola Cesarea Volubilis Pergamo
10.00-13.30 Apertura Segreteria e Registrazione
13.30-16.30 Incontro Scuole RaccontART HIV

Pre-Conference advanced course

HIV Reservoir

Pre-Conference advanced course

Le infezioni opportunistiche: sfide diagnostiche e problematiche cliniche

Pre-Conference advanced course

La gestione della terapia antiretrovirale: nuove opzioni diagnostiche

Pre-Conference advanced course

Prendere decisioni in sanità: l'approccio GRADE

Pre-Conference advanced course

Competenze avanzate degli infermieri

NADIR'S 20th: is Italy focused in achieving the 4th 90?
16.30-17.30

Satellite Symposium

Shaping the future in HIV

 

 

 

 

 

 
17.30-20.30

Auditorium

ICAR 2018 Opening Session

Introducing ICAR 2018
Authorities' welcome addresses

Mauro Moroni memorial Lecture

ICAR-CROI Awards 2018 for young Italian investigators

Opening Lectures

20.30-22.30 ICAR 2018 Welcome Reception
  • Auditorium
    13.30-16.30 Incontro Scuole RaccontART HIV

    Incontro Scuole RaccontART HIV

    Moderatori: F. Ceccherini - Silberstein, M. Errico

    13.30 - 14.00 Introduzione. obiettivi dell'incontro, presentazione della Giuria Artistica e Scientifica e degli Istituti Scolastici in Concorso
    F. Ceccherini - Silberstein, M. Errico
    14.00 - 16.00 Presentazione delle Opere candidate al Concorso
    16.00 - 16.30 Premiazione delle Opere vincitrici
    M. Andreoni, A. Antinori, C.F. Perno
    16.30-17.30

    Satellite Symposium

    Shaping the future in HIV

    Unrestricted educational grant:

    Satellite Symposium

    Shaping the future in HIV

    HAART therapy has completely transformed the future of PLWHIV giving them the same life expectancy than general population. Today ARV drugs are easy to take, powerful, well tollerated and safe. But do we have all the picture clear and under control?  The aim of the symposium is to understand if there are other parameters we are missing or we should understand more in depht such as residual viremia, inibitory quotient of drug combinations, inflammation, what happens in reservoir, etc. The final objective of therapy today should also consider QoL and long term Health. In this context triple therapy is still the Standard of Care and the backbone is the key for durability.

    Chair: A. d'Arminio Monforte

    16.30 - 16.45 Building blocks for a solid ART
    S. Lo Caputo
    16.45 - 17.00 What else do we need to complete the image?
    M. Borderi
    17.00 - 17.15 ART today: endpoint or starting line?
    F. Maggiolo
    17.15 - 17.30 Discussion of Symposium issues
    17.30-20.30

    ICAR 2018 Opening Session

    Introducing ICAR 2018
    Authorities' welcome addresses

    Mauro Moroni memorial Lecture

    ICAR-CROI Awards 2018 for young Italian investigators

    Keynote Lectures

    ICAR 2018 Opening Session

    Chairs: M. Andreoni, A. Antinori, C.F. Perno

    17.30 - 17.45 Introducing ICAR 2018

    Mauro Moroni Memorial Lecture

    Chairs: G. Antonelli, A. Lazzarin

    18.30 - 19.00 HIV persistance and approaches to cure
    J. Martinez-Picado

    ICAR-CROI Awards 2018 for young Italian HIV investigators

    Chairs: A. De Luca, G. Silvestri

      Selected Italian Investigators
     

    Impaired gut tight junction but preserved ΓΔ and microbial translocation in acute HIV
    E.S. Cannizzo University of Milan, San Paolo Hospital

    Cardiac ventricular disfunction in young vertically infected HIV patients
    E.N. Cavallari Sapienza University of Rome

    Beneficial effect of 6 months of probiotics on asymptomatic neurocognitive impairment
    L. Celani Sapienza University of Rome

    Modulation of HIV restriction factors by blocking CCL2/CCR2 in vitro and in vivo
    D.A. Covino Higher Health Institute, Rome

    Specific CSF viral escape findings compared to pre-cART HIV encephalitis
    V. De Zan Vita-Salute San Raffaele University, Milan

    Variability of HIV-1 V2 Env domain for integrin binding: clinical correlates
    C. Fabrizio University of Bari

    Impact of previous M184V on virological outcome of switch to 3TC-based dual therapies
    R. Gagliardini Cattolica del Sacro Cuore University of Rome

    No change in neurocognitive function after switching from efavirenz to rilpivirine
    G. Lapadula University of Milan-Bicocca, Monza Hospital

    HCV and liver disease increase risk of neurocognitive impairment in HIV+ individuals
    I. Mastrorosa National Institute for Infectious Diseases "L. Spallanzani", Rome

    Impact of determinants of increased vascular risk on neurocognition in HIV+ patients
    I. Mastrorosa National Institute for Infectious Diseases "L. Spallanzani", Rome

    Peripheral and CSF immune activation and inflammation in HIV+ patients starting cART
    E. Merlini University of Milan, San Paolo Hospital

    HIV specific IgM memory B cells dominate in seronegative early-treated children
    E. Morrocchi Bambino Gesù Children Hospital, University of Rome

    Hepatic expression of hsa-miR-125a-5p and fibrosis in overt and occult HBV infection
    L. Onorato Second University of Naples

    Risk and predictors of asymptomatic and symptomatic CSF viral escape in HIV+ patients
    C. Pinnetti National Institute for Infectious Diseases "L. Spallanzani", Rome

    Gain of positive charges in HBsAg C-terminus correlates with HBV-induced liver cancer
    R. Salpini Tor Vergata University of Rome

    HIV-RNA in the olfactory mucosa of HIV-positive patients
    M. Trunfio University of Torino

    Opening Lectures

    Chairs: M. Galli, M.R. Iardino, G. Ippolito

    19.30 - 20.00 Global perspectives on HCV eradication
    P. Easterbrook
    20.00 - 20.30 Challenges in reaching the 4th 90 in Italy
    F. Schloesser
    20.30-22.30 ICAR 2018 Welcome Reception
  • Orange 1
    13.30-16.00

    Pre-Conference advanced course

    HIV Reservoir

    Pre-Conference advanced course

    HIV Reservoir

    La terapia antiretrovirale ha indubbiamente portato ad un allungamento della vita ed a un miglioramento della stessa per le persone HIV-positive che seguiamo in ambulatorio, ma, altrettanto sicuramente, il controllo della replicazione di HIV nel plasma non ha corrisposto ad un controllo altrettanto valido nei serbatoi anatomici e cellulari. Ciò rappresenta il maggiore ostacolo all'eradicazione di HIV. Questo corso ha l'obiettivo di approfondire le tematiche innovative legate alla persistenza del reservoir di HIV, dal punto di vista virologico, laboratoristico e clinico-terapeutico.

    Moderatori: S. Rusconi, M. Santoro

      Dove si nasconde HIV: tessuti, incluso il sistema nervoso centrale, e serbatoi cellulari
    13.30 - 13.50 Il punto di vista del clinico
    P.M. Cinque
    13.50 - 14.10 Il punto di vista del virologo
    C. Alteri
    14.10 - 14.20 Discussione
      I marcatori virologici per monitorare il reservoir virale nelle persone HIV-positive
    14.20 - 14.40 Il punto di vista del clinico
    C. Pinnetti
    14.40 - 15.00 Il punto di vista del virologo
    I. Bon
    15.00 - 15.10 Discussione
      Come colpire il reservoir di HIV durante l'infezione acuta
    15.10 - 15.30 Il punto di vista del clinico
    G. d'Ettorre
    15.30 - 15.50 Il punto di vista del virologo
    I. Abbate
    15.50 - 16.00 Discussione
  • Spalato
    13.30-16.00

    Pre-Conference advanced course

    Le infezioni opportunistiche: sfide diagnostiche e problematiche cliniche

    Pre-Conference advanced course

    Le infezioni opportunistiche: sfide diagnostiche e problematiche cliniche

    Negli ultimi anni le linee di attività dei ricercatori e clinici si sono concentrate, peraltro con notevole successo, sul miglioramento delle strategie di terapia antiretrovirale e prevenzione dell'infezione da HIV. D'altra parte è diminuita l'attenzione sul primo capitolo della storia dell'HIV/AIDS, le infezioni opportunistiche, che ancora oggi rappresentano una importante causa di morbilità e mortalità soprattutto nei pazienti con diagnosi tardiva di infezione da HIV. Di qui la necessità di rinvigorire l'attenzione e l'esperienza per le patologie infettive opportunistiche AIDS-correlate. Lo scopo del corso è quello di fornire aggiornamenti sugli aspetti diagnostici e di gestione clinica delle principali infezioni opportunistiche in corso di AIDS.

    Moderatori: C.M. Mastroianni, C. Mussini

    13.30 - 14.00 Diagnosi delle infezioni opportunistiche nella nuova era della microbiologia
    M. Sanguinetti
    14.00 - 14.30 Diagnostica e gestione clinica della sifilide
    A. Cingolani
    14.30 - 15.00 Micosi invasive emergenti
    C. D'Agostino
    15.00 - 15.30 Infezioni opportunistiche del SNC
    P.M. Cinque
    15.30 - 16.00 Patologie opportunistiche tropicali
    A. Cascio
  • Pola
    13.30-16.00

    Pre-Conference advanced course

    La gestione della terapia antiretrovirale: nuove opzioni diagnostiche

    Pre-Conference advanced course

    La gestione della terapia antiretrovirale: nuove opzioni diagnostiche

    L'evoluzione della patologia da HIV richiede un aggiornamento costante del processo gestionale dei pazienti sieropositivi. Il management deve adattarsi alle condizioni del paziente, sia di tipo infettivologico che legate all'invecchiamento o alle diverse co-morbosità. Lo sfruttare le nuove tecnologie di laboratorio, il rivalutare parametri da tempo utilizzati, l'approfondire aspetti peculiari e lo sfruttare nuove opportunità tecnologiche fanno parte di questo aggiornamento.

    Moderatori: A. Di Biagio, F. Maggiolo

    13.30 - 14.00 Recupero immunologico: linfociti CD4 e cosa altro?
    A. Bandera
    14.00 - 14.30 Viremia residua a basse copie: dalla definizione alla gestione
    S. Parisi
    14.30 - 15.00 Frailty nei pazienti HIV: come definirla e quantizzarla?
    M. Borderi
    15.00 - 15.30 Co-morbosità emergenti: focus su ipertensione
    G.V. De Socio
    15.30 - 16.00 Nuovi strumenti gestionali: calcolatori online, punteggi ed applicazioni informatiche
    S. Lo Caputo
  • Cesarea
    13.30-16.00

    Pre-Conference advanced course

    Prendere decisioni in sanità: l'approccio GRADE

    Pre-Conference advanced course

    Prendere decisioni in sanità: l'approccio GRADE

    Il metodo GRADE (Grading of Recommendations Assessment, Development and Evaluation) nasce dalla necessità di standardizzare e rendere trasparente il processo con cui vengono valutate la qualità delle prove disponibili e la forza delle raccomandazioni per la produzione di linee-guida. Nato nel 2000, è diventato lo strumento di riferimento per la formulazione di raccomandazioni cliniche basate sulle evidenze. Un aspetto peculiare del metodo GRADE è l'integrazione della valutazione della qualità metodologica delle prove disponibili con altri aspetti quali: fattibilità e trasferibilità dell'intervento proposto; benefici e rischi attesi e la loro rilevanza; implicazioni organizzative, economiche, sociali e finanziarie. Lo scopo di questo corso è presentare le caratteristiche principali di questo metodo ed illustrare alcuni casi concreti della sua applicazione nell'ambito delle malattie infettive.

    Moderatori: E. Girardi, G. Madeddu, L. Sarmati

    13.30 - 13.45 Introduzione
    E. Girardi
    13.45 - 14.05 Il metodo GRADE: principi generali
    M. Davoli
    14.05 - 14.25 Il metodo GRADE per la produzione di raccomandazioni cliniche
    L. Amato
    14.25 - 14.50 Formulare un quesito: il metodo PICO e le linee guida Italiane di terapia antiretrovirale
    E. Girardi
    14.50 - 15.15 Valutare le evidenze con GRADE: analisi di pubblicazioni scientifiche
    L. Sarmati
    15.15 - 15.40 GRADE dall'evidenza all'indicazione: guidance ECDC sulla prevenzione e il controllo delle malattie trasmissibili nelle carceri
    G. Madeddu
    15.40 - 16.00 Discussione e conclusioni
    E. Girardi, G. Madeddu, L. Sarmati
  • Volubilis
    13.30-16.00

    Pre-Conference advanced course

    Competenze avanzate degli infermieri

    Pre-Conference advanced course

    Competenze avanzate degli infermieri

    Le competenze avanzate degli infermieri sono, nei fatti, una realtà incontestabile e dalla quale non si può più retrocedere in considerazione dell'accordo Stato-Regioni del 2013 e del comma 566 della Legge di stabilità 2015. Il corso precongressuale vuole con i suoi contenuti dimostrare come gli infermieri mettono già in campo le competenze avanzate acquisite, sia nella pratica clinica che in quella gestionale e di ricerca, con l'obiettivo di dare da un lato qualità all'utente e dall'altro far riconoscere le suddette competenze agli altri componenti del gruppo curante, di cui l'infermiere è una figura cruciale.

    Moderatori: G.P. Oliva, E. Zampieri

    13.30 - 13.45 Saluti e presentazione del corso
    G.P. Oliva, E. Zampieri
      La complessità assistenziale infermieristica in ambito infettivologico
    13.45 - 14.15 Una esperienza di rilevazione con ICA-DAMI nell'INMI Spallanzani
    A. De Angelis
    14.15 - 14.45 Distress Management scale: l'esperienza della UOC Immunodeficienze virali dell'INMI Spallanzani
    F. Cannone, G.P. Oliva
      La gestione dei pazienti affetti da lesioni cutanee difficili
    14.45 - 15.15 Appropriatezza nella continuità assistenziale al paziente con lesioni cutanee difficili
    R.R. Zortea
    15.15 - 15.45 Il paziente affetto da lesioni cutanee difficili infette da germi multiresistenti: un caso clinico
    E. Zampieri, G.P. Oliva
  • Pergamo
    13.30-16.00

    Special event

    NADIR'S 20th: is Italy focused in achieving the 4th 90?

    NADIR'S 20th: is Italy focused in achieving the 4th 90?

    In Italy HIV therapy is available and free of charge to people living with the infection. Nearly the 90% of people in treatment achieve the viral load suppression. By consequence, a health related good quality of life should be the crucial target for the care-giving system. Is this commitment a shared target in Italy? Are all the stakeholders involved in this social and health process? Nadir, twenty years after its foundation, in accordance to its constitutional goals, is exploring this new HIV infection social approach to find a common playing field with all the stakeholders to follow up the settlement of the UNAIDS 4th 90 challenge.

    Chairs: F. Schloesser, S. Vella

    13.30 - 13.40 Welcome
    F. Schloesser, S. Vella
      Are we loosing the importance of the 4th 90?
    Chairs: M. Cascio (Palermo), A. Lazzarin (Milano), B. Marchini (Roma)
    13.40 - 13.55 Managing comorbidities in real life. Is it a challenge?
    S. Marcotullio
    13.55 - 14.10 Self-Perceived quality of life. Is this a neglected issue?
    S. Mattioli
    14.10 - 14.25 PLWH rights. Where are we going?
    M. Oldrini
    14.25 - 14.40 What can SIMIT (Italian Society of Infectious and Tropical Diseases) do for ensuring the 4th 90?
    M. Galli
      Round Table: identifying pragmatic goals for reaching the 4th 90
    Chairs: M. Andreoni (Roma), M.L. Cosmaro (Milano), M. Stagnitta (Firenze)
      on managing comorbidities
    G. Guaraldi
      on self-perceived quality of life
    A. Antinori
      on PLWH rights
    C. Mussini
      Remarks from the room
      Let's not forget Italian detectable PLWH
    Chairs: M.G. Di Benedetto (Catania), M. Farinella (Roma), L. Rancilio (Milano)
    15.40 - 15.55 Are Italian multi-class resistant patients becoming a neglected population?
    A. Castagna
Auditorium Leptis Magna Orange 1 Spalato Pola Cesarea
09.00-10.00

Auditorium

Keynote Lectures
10.10-11.55

Symposium

Towards the elimination of HCV and a cure for HBV

Oral Communications

Antiretroviral therapy: focus on integrase inhibitor

Oral Communications

Virology

 

 

 
12.00-12.45

Sponsored Symposium

Future Challenges in the Long Term Management of HIV

Satellite Symposium

Educate to Eradicate: from commitment to action

 

 

 

 
12.50-13.35

Satellite Symposium

The Protease Inhibitor in present and future

 

Expert Meeting

Towards HCV elimination program in PWID

 

 

 
13.40-14.40

 

 

Expert Meeting

Long-acting antimicrobial therapy for Gram-positive infections: new patient management scenarios

Expert Meeting

Elimination of Hepatitis C in a target population: a tailored strategy

Expert Meeting

Focus Group "Shaping the future in HIV once-daily therapy"

Expert Meeting

New perspectives in the management of HIV infected person clinical path: The App Co.HIV
15.05-16.20

Symposium

Designing strategies for combination prevention

Oral Communications

Clinical Hepatitis I

Oral Communications

Immunology

Poster Discussion

Clinical HIV

 

 
16.25-17.40

Symposium

Tumors and chronic diseases in HIV infected patients: pathogenesis and clinical update

Oral Communications

Hepatitis: basic science and virology

Oral Communications

Social Science, marginalized population

 

 

 
17.45-18.45

Oral Communications

Comorbidities I

Oral Communications

HIV epidemiology and prevention

Poster Discussion

Social Science

Poster Discussion

Immunology

 
  • Auditorium
    09.00-10.00 Keynote Lectures

    Keynote Lectures

    Chairs: R. Cauda, A. d'Arminio Monforte, V. Vullo

    09.00 - 09.30 Cancer immunotherapy: a finally successful approach with potential implications in HIV therapy
    M. Maio
    09.30 - 10.00 New therapeutic options for new and old patients
    A. Castagna
    10.10-11.55

    Symposium

    Towards the elimination of HCV and a cure for HBV

    Symposium

    Towards the elimination of HCV and a cure for HBV

    The availability of pangenotypic oral antivirals has made possible the elimination of HCV; a crucial role will be played by the elimination of virus reservoire in marginalized populations; thus, the treatment of PWID and prisoners will have pivotal role in any plan for eradication of HCV infection. The lifelong administration of anti HBV drugs allows only a suppression of viral replication, so it is important to understand if they could be stopped in some patients and if new treatment options may allow to cure HBV infection and eradicate delta coinfection and which are the lab tools to define these new strategies.

    Chairs: G. Angarano, C.M. Mastroianni, M. Puoti

    10.10 - 10.25 HCV in PWID and prison setting
    M. Andreoni
    10.25 - 10.40 When can we stop NUCs in patients with Chronic Hepatitis B?
    G. Taliani
    10.40 - 10.55 New biomarkers for the management of Chronic Hepatitis B
    V. Svicher
    10.55 - 11.10 Update on Hepatitis B cure and emerging issues in Hepatitis D?
    G.B. Gaeta
    11.10 - 11.55 Discussion of Symposium issues
    12.00-12.45

    Sponsored Symposium

    Future Challenges in the Long Term Management of HIV

    Sponsored by:

    Sponsored Symposium

    Future Challenges in the Long Term Management of HIV

    The challenge in the fight against HIV is constantly evolving, and both the clinical management of long-term ARV therapy and the needs of the HIV+ patient have to be taken in account. The long-term control of the disease with ever less impact on patients' lives, the challenge of reducing the toxicity of the therapy, the necessity of research for new drugs and new mechanisms of action are all area to be discussed to choose the best research strategies for the benefit of the PLWHIV. This workshop aims to tell a long-term vision in HIV therapy, both from an epidemiological / virological point of view and also from clinical management, and to trace the next HIV challenges on which clinical research will have to concentrate, foreshadowing which new pharmaceutical paradigms will be needed to succeed.

    Chair: A. d'Arminio Monforte

    12.00 - 12.05 Introduction to ViiV HC SE Symposium and rational for the topic
    P. Rizzini
    12.05 - 12.20 The virological vision
    M. Zazzi
    12.20 - 12.35 The clinical management vision
    A. Antinori
    12.35 - 12.45 Discussion of Symposium issues and conclusions
    A. d'Arminio Monforte
    12.50-13.35

    Satellite Symposium

    The Protease Inhibitor in present and future

    Unrestricted educational grant:

    Satellite Symposium

    The Protease Inhibitor in present and future

    PIs are an antiretroviral class whose efficacy and effectiveness are well known due to randomized clinical trials and real world experience. Nowadays it is required to offer new therapeutic options confirming the effectiveness and improving the patients' quality of life. The new PI-Single Tablet Regimen responds to these challenges and meets patients' needs, in terms of confirmed virological efficacy and high genetic barrier with improved tolerability and better adherence.

    Chair: M. Galli

    12.50 - 12.55 Introduction
    M. Galli
    12.55 - 13.10 PI evolution: randomized clinical trials in the modern HAART
    A. Castagna
    13.10 - 13.25 PI consolidated experience from clinical trials to real world evidence
    A. Antinori
    13.25 - 13.35 Discussion of Symposium issues and conclusions
    M. Galli
    15.05-16.20

    Symposium

    Designing strategies for combination prevention

    Symposium

    Designing strategies for combination prevention

    Combination prevention for HIV/STIs integrates biomedical, behavioral and structural interventions, since no single HIV prevention approach alone can stop the epidemic. Achieving the 2020 and 2030 targets will require focused combination prevention efforts including condom provision, community based testing, immediate ART initiation, PrEP and Harm Reduction measures for people who inject drugs. The symposium will try to give a picture of the present situation in Italy and to identify the next steps.

    Chairs: S. Mattioli, V. Puro, G. Rezza

    15.05 - 15.20 Planning an effective mix of prevention interventions
    E. Girardi
    15.20 - 15.35 Community based testing in Italy: from demonstration projects to routine offer
    M.L. Cosmaro
    15.35 - 15.50 Sexually transmitted infections as an indicator of at risk sexual behaviors in Italy
    B. Suligoi
    15.50 - 16.05 Transgenders: a hidden key population
    G. Lapadula
    16.05 - 16.20 Discussion of Symposium issues
    16.25-18.00

    Symposium

    Tumors and chronic diseases in HIV infected patients: pathogenesis and clinical update

    Symposium

    Tumors and chronic diseases in HIV infected patients: pathogenesis and clinical update

    Tumors and chronic diseases represent a substantial cause of mortality and disability in the late-ART era. Although ART suppresses HIV replication in the great majority of treated people, residual persistent immune activation might favor the development of these conditions. This session will provide a clinical update and cover their pathogenesis, including the possible link with chronic inflammation.

    Chairs: A. Cingolani, P.M. Cinque, A. De Luca

    16.25 - 16.45 New insights in antimicrobial and antifungal therapy in immunocompromised setting
    C. Viscoli
    16.45 - 17.05 HIV-associated vasculopathy in stroke pathogenesis
    L.A. Benjamin
    17.05 - 17.25 HIV infection, gender and HPV risk of cancer
    S. Franceschi
    17.25 - 17.45 Lymphoma pathogenesis in the late cART era and possible role of HIV persistence
    E. Cesarman
    17.45 - 18.00 Discussion of Symposium issues
  • Leptis Magna
    10.10-11.55

    Oral Communications

    Antiretroviral therapy: focus on integrase inhibitor

    Oral Communications

    Antiretroviral therapy: focus on integrase inhibitor

    Chairs: F. Castelli, N. Gianotti, L. Sighinolfi

    10.10 - 10.25 The new frontier in HIV drug resistance: the integrase inhibitors
    D. Armenia
    12.00-12.45

    Satellite Symposium

    Educate to Eradicate: from commitment to action

    Unrestricted educational grant:

    Satellite Symposium

    Educate to Eradicate: from commitment to action

    The WHO has set an ambitious goal to eliminate HCV as a major public health threat by 2030: reduce new HCV infections by 80%, the number of HCV deaths by 65%, increase HCV diagnoses to 90% and the number of eligible persons receiving HCV treatment to 80%. The availability of simple and tolerable DAA therapies for HCV infection with cure rates >90% has brought considerable optimism to people working in HCV. However, the availability of open access to HCV cure is going to change progressively the HCV patients' demographics at point of care, bringing novel challenges in the care cascade. The symposium will focus on addressing the challenges of achieving elimination of hepatitis C with the aim to go beyond the data and breaking down the obstacles that continue to hinder the full implementation of available diagnostic and treatment options.

    Chairs: M. Andreoni, C.F. Perno

    12.00 - 12.15 Beyond the liver: time for a new model for HCV patient management?
    M. Puoti
    12.15 - 12.30 The road toward HCV eradication: from the National plan to individual patient's needs
    C. Mussini
    12.30 - 12.45 Discussion of Symposium issues
    15.05-16.20

    Oral Communications

    Clinical Hepatitis I

    Oral Communications

    Clinical Hepatitis I

    Chairs: R. Bruno, G. Carosi, G. D'Offizi

    15.05 - 15.20 HCV reinfection in high risk populations
    P. Ingiliz
    16.25-17.40

    Oral Communications

    Hepatitis: basic science and virology

    Oral Communications

    Hepatitis: basic science and virology

    Chairs: F. Baldanti, N. Coppola, C. Torti

    16.25 - 16.40 HCV resistance
    F. Ceccherini - Silberstein
    17.45-18.45

    Oral Communications

    Comorbidities I

    Oral Communications

    Comorbidities I

    Chairs: M. Borderi, A.M. Cattelan, G. Madeddu

  • Orange 1
    10.10-11.55

    Oral Communications

    Virology

    Oral Communications

    Virology

    Chairs: M.R. Capobianchi, V. Ghisetti, M.C. Re

    10.10 - 10.25 The clinical virology laboratory in the management of patients with maximal virologic suppression
    O. Turriziani
    12.50-13.35

    Expert Meeting

    Towards HCV elimination program in PWID

    Unrestricted educational grant:

    Expert Meeting

    Towards HCV elimination program in PWID

    PWIDs currently represent the major reservoir of the disease and the main source of infection. Injection drug use is responsible for 23% of the new infections and each PWID with HCV infection can infect at least 20 other consumers, within the first 3 years of the start of the infection. The availability of therapeutic tools capable of curing the HCV could allow to develop integrated models of patients' management with the aim to implement the screening, prevent reinfections through the increase of harm-reduction actions and improve the quality of life of patients. Despite access to care is now ensured to all persons with HCV, it is still difficult to reach high-risk behavior population as PWIDs who, in terms of public health, should be the primary target for the treatment of the disease. The Expert Meeting will underline critical factors to shape a successful elimination program.

    12.50 - 13.35 Towards HCV elimination program in PWID
    M. Andreoni, F.A. Nava
    13.40-14.40

    Expert Meeting

    Long-acting antimicrobial therapy for Gram-positive infections: new patient management scenarios

    Expert Meeting

    Long-acting antimicrobial therapy for Gram-positive infections: new patient management scenarios

    Acute bacterial skin and skin-structure infection (ABSSSI) is a frequent cause of morbidity in hospital settings. Staphylococcus aureus is the most frequent cause of these infections, and methicillin-resistant S. aureus (MRSA) represents the first resistant pathogen involved in complicated forms of skin and soft-tissue infections (cSSTI). Identification of early switch and early discharge opportunities for hospitalized patients with ABSSSI due to MRSA could lead to a significant reduction in length of stay, providing a mechanism for improving outcomes and increasing efficacy: the use of long-acting antibiotics seems to be the best strategy. This approach could profoundly modify the management of these infections by reducing or in some cases eliminating hospitalization costs and risks.

    Chair: M. Galli

    13.40 - 14.40 Long-acting antimicrobial therapy for Gram-positive infections: new patient management scenarios
    M. Venditti
    15.05-16.20

    Oral Communications

    Immunology

    Oral Communications

    Immunology

    Chairs: M.S. Clerici, A. De Maria, G. Poli

    15.05 - 15.20 Current role of bone marrow transplantation in HIV-associated lymphoproliferative diseases
    A. Bandera
    16.25-17.40

    Oral Communications

    Social Science, marginalized population

    Oral Communications

    Social Science, marginalized population

    Chairs: M.G. Di Benedetto, B. Marchini, S. Marcotullio

    16.25 - 16.40 Chemsex recreational drug use and antiretroviral treatment
    M. Zaccarelli
    17.45-18.45

    Oral Communications

    HIV epidemiology and prevention

    Oral Communications

    HIV epidemiology and prevention

    Chairs: B.M. Celesia, S. Nozza, G. Parruti

  • Spalato
    13.40-14.40

    Expert Meeting

    Elimination of Hepatitis C in a target population: a tailored strategy

    Unrestricted educational grant:

    Expert Meeting

    Elimination of Hepatitis C in a target population: a tailored strategy

    In Italy, the incidence of HCV infections among the general population is approximately 1%, and there is a considerable burden of HCV infections among people with addictions, especially those who inject drugs (PWID). Direct-acting antiviral therapies (DAA) with HCV cure rates >95% provide an opportunity to reverse rising trends in HCV-related morbidity and mortality and reduce incidence. Aim of this Expert Meeting is to share the definition of a diagnostic therapeutic strategy to heradicate HCV infections in those special population.

    13.40 - 14.40 Elimination of Hepatitis C in a target population: a tailored strategy
    M. Andreoni, S. Regio
    15.05-16.05

    Poster Discussion

    Clinical HIV

    Poster Discussion

    Clinical HIV

    Chairs: S. Babudieri, T. Bini, M.A. Di Pietro

    17.45-18.45

    Poster Discussion

    Social Science

    Poster Discussion

    Social Science

    Chairs: M. Oldrini, L.A.R. Rancilio

  • Pola
    13.40-14.40

    Expert Meeting

    Focus Group "Shaping the future in HIV once-daily therapy"

    Expert Meeting

    Focus Group "Shaping the future in HIV once-daily therapy"

    Nowadays the effectiveness of HIV treatments is mainly due to the evolution ARV has undergone in the last years. The class of integrase inhibitors (INSTI) is today the most widely used as third antiretroviral combination drug and constitutes the present and the future of this therapeutic area. INSTI is widely used for its efficacy, tolerability, low rate of interactions with other drugs and peculiar and decisive mechanism of antiviral action. A Focus Group composed by specialists and experts in the treatment of HIV infection will discuss the issues of the new anti-retroviral therapy (ARV) once daily therapeutic options.

    Coodinators: A. Antinori, C.F. Perno

      Discussants: A. d'Arminio Monforte (Milano), A. Gori (Monza), A. Lazzarin (Milano), C. Mussini (Modena)
    17.45-18.45

    Poster Discussion

    Immunology

    Poster Discussion

    Immunology

    Chairs: F. Baldelli, L. Calza, G. d'Ettorre

  • Cesarea
    13.40-14.40

    Expert Meeting

    New perspectives in the management of HIV infected person clinical path: The App Co.HIV

    Unrestricted educational grant:

    Expert Meeting

    New perspectives in the management of HIV infected person clinical path: The App Co.HIV

    The management of people with HIV infection in antiretroviral therapy, which have a prevalence and incidence of co-morbidity higher than the general population of equal sex and age, today requires an increase in the complexity of both the screening of vulnerabilities by co-morbidity and the management of frequent contemporary poly-pharmacy. The 15-20 minutes available to the clinic for the visit do not allow the normal follow-up of HIV / HAART infection and, at the same time, the search for vulnerability for all comorbidities (nephrology, endocrinology, bone, cardiovascular, neurological, dermatological, gynecological, metabolic, psychiatric). Dedicated to the screening and management of co-morbidities in HIV, the new app allows a simple user interface to select the organ for screening or management of each single comorbidity, enter some specific parameters (sex, age, etc ... ), complete a checklist to verify the patient's exact conditions, access the most appropriate online tools for the evaluation of each specific case with a guide to the reading of the results obtained, and also access the specific sections of the national guidelines and international recommendations. Specific anamnesis and objective examination aimed at the screening of co-morbidities, predictive risk algorithms for co-morbidity, blood and urinary tests specific for single co-morbidity, request for first level instrumental exams, request for specialist advice and second level instrumental examinations: these are his areas of use.

    13.40 - 14.40 New technological tools for the management of co-morbidities. The App Co.HIV: rationale, structure and interactive practical tests
    A. Porreca
Auditorium Leptis Magna Orange 1 Spalato Pola
09.00-10.00

Auditorium

Keynote Lectures
10.10-11.55

Symposium

New insights in viro-immunological pathogenesis in HIV

Oral Communications

Clinical Hepatitis II

Oral Communications

Virology and pharmacology

Poster Discussion

Comorbidities

 
12.00-12.45

Satellite Symposium

HIV & HCV: moving forward through tailored approaches

 

 

 

 
12.50-13.35

Satellite Symposium

Innovation in the treatment of HIV: definition and medical needs identification

 

 

 

 
13.45-15.00

Oral Communications

Clinical HIV

Oral Communications

Comorbidities II

Oral Communications

Finding the undiagnosed and preventing new infections

Poster Discussion

Hepatitis

Poster Discussion

Basic science and virology
15.00-16.15

Auditorium

Symposium

Management of HIV therapy in Special Populations
16.15-16.45

Auditorium

ICAR 2018 Best Poster and SIMIT Special Awards
16.45-17.00

Auditorium

ICAR 2018 Closing remarks
  • Auditorium
    09.00-10.00 Keynote Lectures

    Keynote Lectures

    Chairs: A. Chirianni, G.M. Corbelli, C. Mussini

    09.00 - 09.30 The role of microbiome in HIV acquisition and progression and response to cART
    G.C. Marchetti
    09.30 - 10.00 Challenges with PrEP implementation: the French experience
    J. Molina
    10.10-11.55

    Symposium

    New insights in viro-immunological pathogenesis in HIV

    Symposium

    New insights in viro-immunological pathogenesis in HIV

    The viro-immunological pathogenesis of HIV-infection is not fully understood, and results from a despite complex equilibrium between viral factors, host response, co-infections. Several approaches have been attempted to reach a cure, that include cART treatment in the earliest stages of the infection, as well as immune based approaches aimed at the containment of immune activation/inflammation, HIV-reservoir, and at the reconstitution of the immune competence to fully contain viral replication even in tissue (sanctuaries) once cART is stopped. The newest aspects of both HIV pathogenesis and cure will be discussed.

    Chairs: G. Palù, M. Tavio, M. Zazzi

    10.10 - 10.25 Host and viral factors in HIV and AIDS pathogenesis
    G. Silvestri
    10.25 - 10.40 Recent progress in anti-HIV broadly neutralizing antibodies
    G. Scarlatti
    10.40 - 10.55 Immune and viral correlates of earliest HIV infection
    G. Tambussi
    10.55 - 11.10 Circulating and tissue reservoirs in HIV pathogenesis and cure
    C. Agrati
    11.10 - 11.25 Role of viral coinfections in residual immune-activation
    M. Lichtner
    11.25 - 11.55 Discussion of Symposium issues
    12.00-12.45

    Satellite Symposium

    HIV & HCV: moving forward through tailored approaches

    Unrestricted educational grant:

    Satellite Symposium

    HIV & HCV: moving forward through tailored approaches

    Innovation, as part of recent HIV and HCV therapeutic approaches, is essential to ensure and maximize treatment effectiveness. Versatility and therapy personalization are now crucial treatment imperatives which contribute to guarantee treatment durability, high efficacy and tolerability to ensure patients' every day high quality of life.

    Chairs: A. d'Arminio Monforte, M. Puoti

    12.00 - 12.15 Patient centricity beyond HCV
    G. Taliani
    12.15 - 12.30 Versatility: the key success factor in the management of HIV+ patients
    A. Antinori
    12.30 - 12.45 Discussion of Symposium issues
    12.50-13.35

    Satellite Symposium

    Innovation in the treatment of HIV: definition and medical needs identification

    Con il supporto incondizionato di:

    Satellite Symposium

    Innovation in the treatment of HIV: definition and medical needs identification

    The fight against HIV / AIDS is not yet won, and much remains to be done. The commitment of academic and pharmaceutical research must therefore be maintained, strengthened and directed towards the solution of identified and shared health needs. In this perspective, the challenge of pharmacological innovation is certainly fundamental, with objectives ranging from the long-term control of the disease with ever less impact on the lives of patients, the challenge of reducing the toxicity of therapy, the need for research into new molecules and mechanisms of action necessary to fight a virus that can hide in the reservoir of the organism and become resistant to the different classes of antiretrovirals. This workshop aims to address the issue of innovation in HIV therapy, its definition and evaluation, evaluating it according to the perspective of the various stakeholders able to express the needs that are still to be dealt with effectively through research: the scientific community and the people living with HIV.

    Chair: A. Antinori

    12.50 - 12.55 Introduction
    A. Antinori
    12.55 - 13.10 The vision of scientific community
    M. Andreoni
    13.10 - 13.25 The vision of PLWHIV community
    G.M. Corbelli
    13.25 - 13.35 Discussion of Symposium issues and conclusions
    A. Antinori
    13.45-15.00

    Oral Communications

    Clinical HIV

    Oral Communications

    Clinical HIV

    Chairs: A. Di Biagio, S. Di Giambenedetto, R. Maserati

    15.00-16.15

    Symposium

    Management of HIV therapy in Special Populations

    Symposium

    Management of HIV therapy in Special Populations

    cART is chronic therapy that requires adjustments according to the stage of infection. Treating a newly acquired acute infection is completely different from treating a multi-experienced patient harboring a virus with multiple resistance. The optimal management of cART, however must be modulated on the characteristics of patients, too. Only the comprehensive inclusion of these multiple variables leads to the optimal management of the chronic therapy.

    Chairs: S. Lo Caputo, F. Maggiolo, G. Mazzola

    15.00 - 15.15 Acute Infections
    A. Gori
    15.15 - 15.30 Multi-failed
    S. Rusconi
    15.30 - 15.45 Pregnancy
    G. Liuzzi
    15.45 - 16.00 Elderly
    G. Guaraldi
    16.00 - 16.15 Discussion of Symposium issues
    16.15-16.45 ICAR 2018 Best Poster
    and SIMIT Special Awards

    ICAR 2018 Best Poster and SIMIT Special Awards

    Chairs: M. Andreoni, A. Antinori, C.F. Perno

    16.15 - 16.30 Best Poster Award
    M. Andreoni, A. Antinori, C.F. Perno
    16.30 - 16.45 SIMIT Awards to Best Oral Communications for Young Researchers
    M. Galli
    16.45-17.00 ICAR 2018 Closing remarks

    Closing remarks

    Chairs: M. Andreoni, A. Antinori, C.F. Perno

      Closing remarks
    M. Andreoni, A. Antinori
  • Leptis Magna
    10.10-11.55

    Oral Communications

    Clinical Hepatitis II

    Oral Communications

    Clinical Hepatitis II

    Chairs: O. Armignacco, F. Benanti, F. Mazzotta

    10.10 - 10.25 When is it safe to discontinue HBV prophylaxis in immunosuppressed patients?
    L. Sarmati
    13.45-15.00

    Oral Communications

    Comorbidities II

    Oral Communications

    Comorbidities II

    Chairs: P. Bonfanti, C. Gervasoni, P. Maggi

  • Orange 1
    10.10-11.55

    Oral Communications

    Virology and pharmacology

    Oral Communications

    Virology and pharmacology

    Chairs: M. Clementi, L. Lopalco, G. Nunnari

    10.10 - 10.25 Mitochondrial toxicity of NRTI: time to rethinking?
    A. Cossarizza
    11.40 - 11.55 Fundamentals of nanopharmacology applied to antiretrovirals
    S. Bonora
    13.45-15.00

    Oral Communications

    Finding the undiagnosed and preventing new infections

    Oral Communications

    Finding the undiagnosed and preventing new infections

    Chairs: M. Breveglieri, M. Farinella, M. Stagnitta

  • Spalato
    10.10-11.25

    Poster Discussion

    Comorbidities

    Poster Discussion

    Comorbidities

    Chairs: D. Ripamonti, A. Saracino, G. Sterrantino

    13.45-15.00

    Poster Discussion

    Hepatitis

    Poster Discussion

    Hepatitis

    Chairs: V. Cento, A. Giacometti, G. Starnini

  • Pola
    13.45-15.00

    Poster Discussion

    Basic science and virology

    Poster Discussion

    Basic science and virology

    Chairs: P. Bagnarelli, S. Parisi, M. Santoro

Poster Area
00.00-00.00

Poster Exibition

Poster Exibition
  • Poster Area
    00.00-00.00

    Poster Exibition

    Poster Exibition

    Poster Exibition

    Poster Exibition

      Antiretroviral therapy
      P 1 - Liver enzyme elevations according to the first line cART regimen: real life data from the ICONA cohort
    L. Taramasso, P. Lorenzini, A. Di Biagio, M. Lichtner, G. Marchetti, R. Rossotti, G. Lapadula, D. Minisci, F. Vichi, A. Antinori, S. Bonora, A. d'Arminio Monforte for ICONA Foundation Study Group
      P 2 - Therapy with darunavir/cobicistat impacts on total cholesterol and glomerular filtration rate
    L. Taramasso, E. Ricci, A. Cascio, B. Menzaghi, L. Valsecchi, N. Squillace, G.V. De Socio, C. Dentone, P. Maggi, C. Martinelli, L. Calza, M. Garau, P. Bonfanti, A. Di Biagio, on Behalf of CISAI study group
      P 3 - Copy-years viremia in HIV-1 patients treated for a long time: risk of virological failure and association with inflammation markers
    F. Falasca, L. Mazzuti, E. Cinquina, G. d’ Ettorre, I. Mezzaroma, M. Falciano, G. Antonelli, O. Turriziani
      P 4 - Metabolic and renal impact of switching from boosted PIs to INI-containing regimens in a monocentric cohort of drug-experienced HIV-positive subjects
    A. Giacomelli, A. Ranzani, E. Gervasi, L. Oreni, T. Formenti, V. Di Cristo, S. De Rose, M. Franzetti, A.L. Ridolfo, M. Galli, S. Rusconi
      P 5 - Changes in lipids profile and eGFR after switching from darunavir/ritonavir (DRV/r) to darunavir/cobicistat (DRV/c)- based dual therapy: a multicenter analysis
    A. Vergori, P. Lorenzini, A. Giannetti, S. Di Giambenedetto, R. Bellagamba, G. Sterrantino, E. Schiaroli, D. Francisci, S. Cicalini, A. Latini, I. Mezzaroma, M. Lichtner, F. Di Sora, G. D’Ettorre, G. Maffongelli, A. Antinori, M. Zaccarelli
      P 6 - Reasons for choosing darunavir/ritonavir 600/100 mg twice daily vs. 800/100 mg once daily in treatment-naïve patients: 10 years data from the ICONA cohort
    A. Tavelli, M. Palma, S. Lo Caputo, G. Madeddu, P. Bonfanti, B. Menzaghi, S. Nozza , A. Antinori, R. Termini, A. d’Arminio Monforte
      P 7 - Dolutegravir plus rilpivirine versus dolutegravir plus lamivudine: a comparison between two dolutegravir-based 2-drug regimens from a multicenter cohort of treatment-experienced HIV-1 infected patients
    A. Ciccullo, G. Baldin, A. Capetti, S. Rusconi, G. Sterrantino, L. Celani, S. Modica, A. Latini, A. Dusina, M.V. Cossu, S. Restelli, A. De Luca, S. Di Giambenedetto
      P 8 - Efficacy and safety of 2-drug combination antiretroviral therapy in clinical practice: results from a single center study
    B. Rossetti, G. Marri, A. Gonnelli, L. Toscano, D. Marri, P. Galluzzi, F. Pippi, N. Carnicelli, C. Malcontenti, C. Puttini, R. Gagliardini, F. Montagnani, G. Zanelli, M. Zazzi, A. De Luca
      P 9 - Lack of excess concentration-related side effects in patients on dolutegravir plus atazanavir dual therapy compared to other dual regimens
    A.F. Capetti, C. Atzori, M.V. Cossu, I. Gallazzi, M. Piscaglia, P. Meraviglia, D. Cattaneo, G. Rizzardini
      P 10 - Characteristics and outcomes of naïve HIV-patients treated with Single Tablet Regimens. A single center experience
    M. De Masi, V. Malagnino, G. Maffongelli, L. Campogiani, T. Mulas, L. Coppola, M. Compagno, A. Gentile, P. Vitale, N. Cesta, L. Sarmati, M. Andreoni
      P 11 - Retrospective analysis on determinant factors of efficacy and safety of switch therapies to darunavir boosted with cobicistat (DRV/c) in different regimens
    A. Vergori, P. Lorenzini, A. Giannetti, A. Antinori, M. Palma, R. Termini, M. Zaccarelli
      P 12 - Evaluation of factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen
    D. Armenia, C. Gori, A. Bertoli, V. Borghi, M. Zaccarelli, A. Di Biagio, B. Bruzzone, L. Fabeni, W. Gennari, D. Pizzi, A. Giannetti, A. Vergori, I. Mastrorosa, A. Latini, M. Colafigli, C. Cerva, R. Marocco, M. Andreoni, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, M.M. Santoro
      P 13 - Dolutegravir-based dual therapy durability in clinical practice: results from the SCOLTA cohort
    G. Madeddu, E. Ricci, R. Gulminetti, G. Orofino, A. Di Biagio, G.V.L. De Socio, M.S. Mameli, N. Squillace, B.M. Celesia, B. Menzaghi, C. Martinelli, S. Rusconi, C. Bellacosa, F. Vichi, S. Passerini, L. Valsecchi, L. Calza, C. Dentone, G. Angioni, K. Falasca, G.F. Pellicanò, P. Bonfanti, C.I.S.A.I. Group, Italy
      P 14 - The use of STR drugs in the management of HIV+ patients: analysis and comparison of the years 2016 and 2017
    F. Ferrara, M. Rizzica, A. Ascani, G. Zaccaro, B. Moreno, L. Chirosa, M. Carli, S. Murachelli, A. Antinori
      P 15 - Switch to Dolutegravir-based regimen in the setting of virologic suppression: study of virological and biological parameters
    D. Di Carlo, I. Mezzaroma, G. d’Ettorre, C. Fimiani, M. Calabretto, G. Antonelli, O. Turriziani
      P 16 - Effect of simplification regimens on blood HIV-DNA reservoir compared to triple ART in patients with suppressed HIV-RNA
    C. Orlandi, B. Canovari, Z. Pasquini, F. Barchiesi, M. Magnani, A. Casabianca
      P 17 - Can the new ART regimens influence adherence to guidelines in the clinical practice? Data from 2016-17 at S. Maria Annunziata Hospital, Florence, Tuscany
    F.M. Fusco, F. Vichi, L. Rabatti, M.C. Burla, M. Prato, P. Blanc
      P 18 - Abacavir/Lamivudine/Dolutegravir (Triumeq) associated to liver toxicity in antiretroviral treatment-naive patient with HIV infection
    S. Martini, G. Di Caprio, L. Onorato, A. Cascone, N. Coppola
      P 19 - Protease Inhibitor-based dual regimens in real life
    O. Bargiacchi, C. Bolla, G. Orofino, A. Parisini, M. Farenga, A. Rossati
      P 20 - Safety, efficacy and costs analysis of treatment simplification options in HIV-1 patients: real-world data analysis at Infectious Diseases Unit of University Hospital of Salerno
    S. Madonia, N. Boffa, F.S. Mennini, P. Sciattella
      Bacterial and fungal infections in immunocompromised host
      P 21 - Are Antifungal Stewardship Programs in Immunocompromised patients needed? An Italian teaching hospital experience
    S. Lardo, D. Faliero, A. De Luca, L. Pavan
      P 22 - Antimicrobial Stewardship in Immunocompromised Hosts: a snapshot
    D. Faliero, S. Lardo, A. De Luca, L. Pavan
      P 23 - Disseminated disease caused by Mycobacterium simiae in a patient with AIDS
    S.B. Morella, S.R. Bruno, S. Sica, S.M. Ferrara, T.A. Santantonio
      Clinical HIV
      P 24 - HIV infection, but not HAART, is independently associated with increased aortic stiffness and early vascular aging
    M. Trizzino, G.J. Mulè, G. Mulè, G. Geraci, P. Colletti, G. Mazzola, C. Iaria, C. Imburgia, C. Colomba, S. Cottone, A. Cascio
      P 25 - Impact of integrase strand transfer inhibitor (INSTI) on body composition in a real-life setting
    A. Bonazza, S. Zona, M. Menozzi, A. Raimondi, C. Monari, M. Digaetano, A. Santoro, V. Borghi, C. Mussini, G. Guaraldi
      P 26 - Changing face of HIV infection and ageing in two cohorts of older patients cross-sectionally observed in 2007 and in 2016
    F. Alessi, A. Marino, M.E. Locatelli, A. Pampaloni, D. Scuderi, M. Maresca, L. Vinci, R. Fontana del Vecchio, R. Bruno, M. Gussio, F. Palermo, B. Cacopardo, B. M. Celesia
      P 27 - Development of a Frailty Index, an HIV Index and a Protective Index from a clinical HIV database
    G. Guaraldi, I. Franconi, O. Theou, L. Wallace, A. Malagoli, R.J.A.H. Eendebak, C. Mussini, K. Rockood
      P 28 - Differences between infections sustained by different viral HIV subtypes in the management of antiretroviral therapy in a Roman hospital: a single experienced center
    G. Maffongelli, M. De Masi, V. Malagnino, T. Mulas, L. Coppola, M. Compagno, L. Campogiani, A. Gentile, C. Cerva, L. Sarmati, M. Andreoni
      P 29 - HIV-RNA rebound during DAA treatment: influence of treatment complexity in HIV/HCV co-infected patients
    A. Palazzo, L. Marinaro, A. Barco, S. Scabini, N. Forni, C. Montrucchio, C. Alcantarini, V. Pirriatore, M.C. Tettoni, L. Trentini, J. Cusato, A. De Nicolò, A. Calcagno, A. D’avolio, G. Di Perri, S. Bonora
      P 30 - Immuno-virological response during antiretroviral therapy in HIV-1 infected patients according to subtype B and non-B
    G. Ciusa, A. Bonazza, G. Cuomo, M. Menozzi, F. Carli, G. Guaraldi, V. Borghi, C. Mussini
      P 31 - Strongyloides stercoralis hyperinfection syndrome in a colombian HIV late presenter
    A. Ricciardi, G. Picchi, A. Cellini, N. Iapadre, M. Mariani, A. Ciccone, F. Marinangeli, G. Bruno, A. Santini, A. Grimaldi
      P 32 - A nutraceutical combination targeting dyslipidemia and subclinical inflammation in HIV-infected patients on stable antiretroviral therapy
    E. Schiaroli, S. Cardaci, V. Bianconi, C. Papalini, M. Pirro, F. Baldelli, D. Francisci
      P 33 - Pneumocystosis as a complication of H1N1 Influenza A infection in an HIV positive patient under effective cART
    I. Franconi, C. Monari, M. Tutone, G. Ciusa, L. Corradi, E. Franceschini, M. Meschiari, C. Puzzolante, G. Cuomo, N. Riva, A. Bianchi, A. Raimondi, W. Gennari, M. Pecorari, G. Guaraldi, C. Mussini
      P 34 - Cardiovascular risk in HIV-positive population: evaluation of the risk and serological markers
    A. Auricchio, C. Ucciferri, F. Vignale, K. Falasca, J. Vecchiet
      P 35 - Abnormal elevation of INR values in a patient during co-administration of E/C/F/TAF and warfarin: a case report
    V. Malagnino, G. Maffongelli, C. Stingone, G. Malerba, E. Teti, M. Capozzi, L. Sarmati, M. Andreoni
      P 36 - Neurotoxoplasmosis in a sicilian HIV reference centre
    A. Cervo, A. De Luca, B. Romanin, F. Scarlata
      P 37 - Immune reconstitution inflammatory syndrome and Cytomegalovirus encephalitis: a case report
    F. Trave, D.C. Cibelli, F. Sozio, A. Consorte, G. Parruti
      HIV-associated and non HIV-associated cancers
      P 38 - Lenalidomide as maintanance therapy for refractory HIV-associated plasmablastic lymphoma: feasible and effective?
    I. De Benedetto, L. Verga, F. A. Brioschi, D. Dalu, C. Gambacorti Passerini, A. Gori, A. Bandera for the Musthal Study Group
      P 39 - HCV-related hepatocellular carcinoma in people with or without HIV coinfection: a survival analysis of a single center cohort
    A. Soria, V. Castelli, E. Colella, N. Squillace, M. Rossi, A. Ciaccio, A. Gori, G.M. Migliorino, G. Lapadula
      P 40 - Sepsis from MDR gram-negative bacteria a lethal complication in a group of HIV positive patients during chemotherapy for hematological malignacies
    C. Cerva, L. Campogiani, G. Maffongelli, G. De Simone, I. Provenzano, D. Nasso, M. Cantonetti, W. Arcese, M. Andreoni, L. Sarmati
      P 41 - Oral plasmablastic lymphoma in HIV: a case report
    F. Trave, D.C. Cibelli, F. Sozio, A.Consorte, G. Parruti
      P 42 - Acute onset of fatal hematologic malignancy in HIV-1 infected patient: Report of a clinical case
    G. Caruana, S. Grignolo, R. Prinapori, V. Cassano, A. Reali, M. Guerra, S. Artioli
      HIV-associated tuberculosis
      P 43 - Quantiferon-TB in HIV-positive patients: prognostic values and factors associated with indeterminate results
    V. Pirriatore, F. Grosso, V. Ghisetti, S. Raviolo, S. Faraoni, I. Motta, M. Milesi, S. Bonora, G. Di Perri, A. Calcagno
      P 44 - Rapid development of unmasking disseminated tuberculosis-related immune reconstitution inflammatory (TB-IRIS) syndrome in a HIV- infected patient after starting combination antiretroviral therapy
    N. Ronzoni, G. Borghero, F. Porcu, A. Sannia, M. Ligas, V. Fiore, G. Madeddu, S. Babudieri
      P 45 - The diagnostic challenge of central nervous system (CNS) lesions in the HIV-infected patient
    M. Caixeiro, F. Peruzzu, R. Jesus, B. Flor de Lima, D. Trigo, M.J. Lopes, J. Batista, P. Pacheco
      Coinfections/sexually transmitted infections
      P 46 - Predictive score of Neurosyphilis (NS) in HIV infected persons: when to perform a lumbar puncture?
    L. Celani, C. Borrazzo, A. Lazzaro, S. Giuliano, S. Savinelli, E.N. Cavallari, G. Corano-Scheri, C. Pinacchio, A. Vullo, G. Ceccarelli, C.M. Mastroianni, G. d'Ettorre
      P 47 - Chemsex and risk of Sexually Transmitted Infections (STI): a pilot survey
    M. Colafigli, F. Roscini, C. Ancona, S. Foracappa, A.E. Levi, M. Frasca, D. Orsini, L. Alei, M.G. Donà, M. Giuliani, A. Cristaudo, A. Latini
      P 48 - Scaling up Hepatitis A vaccination through a community-based intervention among MSM population during 2016-2017 epidemic outbreak
    S. Coladonato, L. Badia, V. Guardigni, A. Gianninoni, M.C. Risi, P. Viale, G. Verucchi, S. Mattioli
      P 49 - The impact of multiple HPV-types on the clinical outcome of HPV infection
    L. Ronga, G. Addati, R. Magrone, A. Abbasciano, D. Di Carlo, G. Miragliotta, R. Del Prete
      P 50 - Cerebrospinal fluid/plasma biomakers in patients with suspected neurosyphilis
    M. Scarvaglieri, L. Di Girolamo, S. Audagnotto, A. Lucchini, C. Costa, L. Mighetto, G. Di Perri, I. Dal Conte, A. Calcagno
      P 51 - An unusual case of hepatic syphilis mimicking a hepatocellular carcinoma
    L. Bianchi, V. Bellelli, G. Russo, G. d’Ettorre, C. D’Agostino, A. Ciardi, M.R. Ciardi, V. Vullo
      P 52 - Improvement in quantitative detection of Human Herpesvirus 6 with a ready-to-use PCR-based Real Time PCR assay
    D. Rigamonti, M. Gramegna, M. Ballarini, M.L. Incandela, L.J. Turner, G. Ferri, L. Bavagnoli, L. Spinelli
      Comorbidities HIV and HCV
      P 53 - Prevalence of thyroid diseases in a cohort of HIV-infected people of Northern Italy
    E. Quiros-Roldan, A. Ferraresi, T. Della Giustina, I. Izzo, M. Properzi, A. Bonito, A. Celotti, M.C. Pezzoli, R. Allegri, F. Castelnuovo, E. Focà, F. Castelli
      P 54 - Longitudinal evaluation of neurocognitive performances in antiretroviral-treated HIV/HCV co-infected patients receiving Directly-Acting Antivirals
    I. Mastrorosa, P. Lorenzini, C. Pinnetti, A.C. Brita, G. Fabbri, A. Vergori, M. Zaccarelli, A. Ammassari, A. Antinori
      P 55 - Which factors delay the HCV treatment in patients with HIV/HCV co-infection? The HCV Cascade of Care among HIV+ patients at S. Maria Annunziata Hospital, Florence
    F.M. Fusco, E. Salomoni, A. Poggi, F. Vichi, A. Degli Esposti, P. Pierotti, F. Baragli, F. Esperti, M. Di Pietro, P. Blanc
      P 56 - Markers of cumulative exposure to HIV viremia predict hepatocellular carcinoma occurrence in HIV patients treated with DAAs for Hepatitis C
    V. Guardigni, A. Casabianca, S. Coladonato, L. Badia, P. Viale, G. Verucchi
      P 57 - Clinical experience with dolutegravir in HIV-HCV co-infected patients treated with Direct-acting Antivirals
    S.T. Kiros, F. Lagi, I. Campolmi, S. Giachè, D. Bartolozzi, A. Bartoloni, G. Sterrantino
      P 58 - Evaluation of transient detectable HIV-RNA (blips) in HIV/HCV coinfected patients during therapy with direct acting antivirals: the experience of Infectious Disease Unit of Verona
    D. Piacentini, S. Chiesi, S. Rizzardo, G.Carolo, E. Lattuada, E. Concia, E. Tacconelli, M. Lanzafame
      P 59 - Impact of HCV eradication on lipidic, glycemic and renal parameters in HIV+ co-infected patients
    E. Milano, C. Fabrizio, L. Scudeller, N. de Gennaro, N. Ladisa, L. Monno, A. Saracino, G. Angarano
      P 60 - Significant improvement in liver steatosis after switching from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with nonalcoholic fatty liver disease (NAFLD)
    L. Calza, M. Borderi, V. Colangeli, S. Coladonato, B. Tazza, G. Fornaro, L. Badia, V. Guardigni, G. Verucchi, P. Viale
      P 61 - HBV/HCV/HDV coinfection HIV positive patient: analysis of reciprocal viral dynamics in plasma, PBMC and liver tissue
    G. Di Caprio, S. Martini, C. Monari, A. Cascone, N. Coppola
      P 62 - Alexithymia in a group of HIV/HCV infected patients. Preliminary data
    M. Vitale, A. Cappabianca, S. Madonia, N. Boffa
      Clinical Hepatitis
      P 63 - Does baseline liver stiffness value influence fibrosis outcome after direct-acting antiviral treatment in HIV-HCV coinfected patients?
    G. Fornaro, V. Guardigni, F. Ravaioli, L. Badia, P.L. Viale, D. Festi, G. Verucchi
      P 64 - Vitamin D deficiency and health-related quality of life in chronic Hepatitis C
    D. Palazzo, E. Biliotti, R. Esvan, F. Severini, L. Volpicelli, P. Perinelli, P. Maida, M. Spaziante, L. Fontanelli Sulekova, C. Franchi, M. De Angelis, G. Iaiani, P. Rucci, G. Taliani
      P 65 - HCV and hepatic steatosis measured by Transient Elastography (CAP): the impact of HCV eradication in a population of patients treated with DAAs
    E. Salomoni, A. Degli Esposti, A. Gabbuti, P. Pierotti, F. Vichi, F. Baragli, C. Blè, F. Esperti, L. Mecocci, P. Blanc
      P 66 - Immune Thrombocytopenic Purpura associated with Hepatitis A infection in a 39-year old man
    G. Parrella, V. Iodice, N. Capoluongo, G. Di Flumeri, R. Viglietti, V. Sangiovanni, A. Chirianni
      P 67 - Hepatitis B virus reactivation sustained by an HBsAg immune-escape mutant isolate in an anti-HBc positive patient in course of Sofosbuvir/Velpatasvir treatment of HCV infection: a case report
    L. Foroghi, V. Malagnino, E. Teti, M. Aragri, C. Cerva, M. De Masi, A. Gentile, R. Salpini, V.C. Di Maio, C. Sarrecchia, M. Andreoni, V. Svicher, F. Ceccherini-Silberstein, L. Sarmati
      DAAs therapy in HCV
      P 68 - Viral dynamics in HCV infected patients with different genotypes during old and new direct-acting antiviral agents combination
    S. Paolucci, F. Novazzi, R. Gulminetti, S. Novati, R. Maserati, G. Barbarini, P. Sacchi, A. Piralla, F. Baldanti
      P 69 - NS5A inhibitor natural resistance associated substitutions (RASs) in a cohort of genotype (GT) 1a and 1b Hepatitis C (HCV) chronically infected patients
    P. Canepa, L. Nicolini, S. Marenco, B. D’Ambrosio, C. Arcuri, G. Guarona, G. Pieri, A. Picciotto, G. Icardi, B. Bruzzone
      P 70 - Response to DAA among HIV-HCV co-infected people who inject drugs (PWID) in clinical practice
    A. Tavelli, A. Cozzi-Lepri, C. Mussini, A. Castagna, A. Saracino, A. Cingolani, B. Menzaghi, G. Lapadula, S. Savinelli, A. Antinori, A. d'Arminio, M. Puoti for Icona Foundation Study Group
      P 71 - Changes in serum lipid profiles in the HIV-HCV co-infected patients treated with direct acting antivirals (DAAs)
    M. Schiavini, F. Niero, A.L. Croci, M. Passerini, S. Landonio, C. Magni, V. Scalzi, S. Vimercati, L. Valsecchi, M. Bolis, S. Passerini, N. Astuti, P. Meraviglia, G. Gubertini, G. Rizzardini
      P 72 - HCV patients and economic resources optimisation: the role of the DAA
    E. Garagiola, L. Ferrario, B. Menzaghi, A. Tebini, G. Rizzardini, M.V. Cossu, E. Foglia, D. Croce
      P 73 - HIV-HCV coinfected patients’ fibrosis improves less after Direct-Acting Antiviral treatment: analysis of a single centre cohort
    S. Oldrini, D. Tomasoni, V. Cappa, S. Zaltron, A. Spinetti, P. Nasta, C. Chirico, C. Carriero, G. Zuglian,F. Castelnuovo, L. Biasi, E. Festa, F. Castelli
      P 74 - Neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) during Direct-Acting Antiviral treatment. Is PLR a predictor of sustained virological response?
    S. Odolini, D. Tomasoni, V. Cappa, S. Zaltron, A. Spinetti, P. Nasta, C. Chirico, C. Carriero, G. Zuglian, F. Castelnuovo, L. Biasi, E. Festa, F. Castelli
      P 75 - Integrated efficacy and safety analysis of Italian population treated with Glecaprevir/Pibrentasvir in phase 3 clinical trials
    A. Aghemo, P. Andreone, G. D’Offizi, S. Fagiuoli, M. Galli, A. Gasbarrini, P. Lampertico, M. Persico, M. Puoti, G. Rizzardini, G. Taliani, E. Villa, M. Vinci, A.L. Zignego, M. Zuin, A. Perretti, S. Petta
      P 76 - Anti-HCV therapy in HIV/HVC co-infected patients
    H. Ernandes, L. Ammari, R. Abdelmalek, A. Berriche, S. Aissa, F. Kanoun, H. Harrabi, B. Kilani, O. Bahri, H.T. Benaissa
      HCV eradication and model to access to care
      P 77 - Hepatitis C micro-elimination Project - ASL Roma 1
    P. Casella, A. Torreggiani, E. Dorigo, A. Lupi, S. Sereno, T. Girolami, E. Biliotti, D. Palazzo, A. Rugova, M. Santori, T. Petrangolini, G. Taliani
      P 78 - Clinical and virological characteristics of two paediatric patients on treatment with DAA
    M. Mazzitelli, N. Marascio, G. Pavia, C. Costa, G. Giuseppe, M.C. Postorino, G.S. Barreca, V. Pisani, M.C. Liberto, A. Focà, C. Torti
      P 79 - A model of care of HCV eliminination in prison: an epidemiological Survey in the the remand Center of Padua
    D. Lageder, V. Grigolin, L. Marcolongo, E. Conti, S. Lobello, F.A. Nava
      P 80 - A model of Harm reduction program in an attenuate custody section for drug users: results and findings from the pilot experience of Padua prison
    M. Rampazzo, V. Minutella, P. Vinti, M. Galdiolo, M. Costacurta, G.B. Padovan, F.A. Nava
      Hepatitis Clinical diagnostics
      P 81 - Low performance of the OraQuick Hepatitis C Virus rapid antibody test in HIV/HCV infected individuals
    S. Vita, I. Pozzetto, I. Mastrini, R. Marocco, L. Fondaco, B. Kertusha, V. Rossi, T. Tieghi, M. Lichtner, e C.M. Mastroianni
      P 82 - HBV molecular epidemiology and clinical condition of immigrants living in Italy
    C. Sagnelli, M. Ciccozzi, L. Alessio, E. Cella, L. Gualdieri, M. Pisaturo, C. Minichini, G. Di Caprio, M. Starace, L. Onorato, M. Capoprese, L. Occhiello, S. Angeletti, G. Scotto, M. Macera, E. Sagnelli, N. Coppola
      P 83 - HCV genetic variability in patients with HCV-genotype 1-related hepatocellular carcinoma
    M. Pisaturo, C. Minichini, M. Starace, L. Occhiello, A. Di Fraia, N. Farella, G. De Stefano, V. Iodice, N. Coppola
      P 84 - HEV antibodies detection: comparison between two different commercially available assays
    P. Caligiuri, E. Furfaro, L.A. Nicolini, M. Mikulska, G. Barisione, R. Cerruti, M. Ferraris, G. Icardi, B. Bruzzone
      Hepatitis Epidemiology
      P 85 - Molecular epidemiology of HAV infection in Liguria: genetic analysis of HAV strains collected from December 2016 to February 2018
    P. Canepa, B. D’Ambrosio, C. Arcuri, L. Santin, C. Dentone, M. Mela, F. Briano, A. Orsi, F. Butera, A. Schenone, G. Icardi, B. Bruzzone
      P 86 - Epidemiology and risk factors for HCV infection among Italian intravenous drug users
    A. Boschini, M. Begnini, R. Poletti, C. Smacchia, C. Sala, G. Castellani, M. Colombo
      P 87 - Epidemiology and risk factors for HCV infection among Italian non-injection drug users
    A. Boschini, M. Begnini, R. Poletti, C. Smacchia, C. Sala, G. Castellani, M. Colombo
      Hepatitis Pathogenesis
      P 88 - Correlation between the hepatic concentrations of miR-125a-5p and the progression of liver damage in patients with overt and occult HBV infection
    L. Onorato, A. Russo, G. de Stefano, C. Minichini, M. Panella, V. Messina, M. Starace, P. Filippini, N. Mosca, L. Alessio, L. Desiato, N. Farella, N. Potenza, E. Sagnelli, N. Coppola
      Hepatitis Treatment
      P 89 - Combination therapy with pegylated interferon and tenofovir in HBV/HDV-infected patients
    A. Maccaro, L. Badia, V. Guardigni, P. Viale, G. Verucchi
      P 90 - Off label retreatment of a patient failed to NS5A based DAAs regimen with advanced liver failure: a case report
    E. Ciracì, S. Semeraro, G. Angarano, L. Monno, L. Lepore, P. Gatti
      P 91 - Treatment with IFN-free regimen in a cohort of patients affected by chronic hepatitis C and psychiatric disorders: a retrospective analysis
    T. Lupia, L. Boglione, G. Cariti, S. Mornese Pinna, G. Di Perri
      HIV Epidemiology
      P 92 - HIV infection among transgender patients: our experience
    C. Papalini, S. Cardaci, S. Bastianelli, S. Pierucci, C. Sfara, F. Baldelli, D. Francisci
      P 93 - Acceptability of HIV rapid test: comparison of capillary whole blood test and oral fluid test in outpatient service for migrants in Italy
    G. Chiaradia, P. Scognamiglio, P. Piselli, C. Angeletti, M. Oldrini, E. Albertini, A. Camposeragna, M. Farinella, D. Lorenzetti, L. Rancilio, G. Ippolito, E. Girardi
      P 94 - Significant spread to the native Italian population of HIV-1 non-B subtypes and worse virological response at week 48 to first-line cART: a single cohort experience in a region with a high migration rate
    I. Izzo, M.A. De Francesco, F. Gargiulo, E. Quiros-Roldan, F. Invernici, F. Castelnuovo, E. Focà, A. Bonito, A. Caruso, F. Castelli
      P 95 - Low prevalence of HTLV1/2 infection in a population of sub-Saharan immigrants living in Southern Italy
    L. Occhiello, L. Alessio, C. Minichini, M. Starace, M. Caroprese, G. Di Caprio, C. Sagnelli, L. Gualdieri, M. Pisaturo, L. Onorato, G. Scotto, M. Macera, S. De Pascalis, E. Sagnelli, N. Coppola
      P 96 - Prevalence of drug resistance and circulating viral subtypes in a real -life cohort of ART naïve HIV positive patients from 2005-2017
    L. Mazzuti, T. Melengu, I. Mezzaroma, G. d'Ettorre, E. Cella, C. Fimiani, G. Iaiani, M. Falciano, M. Ciccozzi, G. Antonelli, O. Turriziani
      P 97 - Impact of tuberculosis and HIV infection on healthcare activities of infectious disease units in the Calabria region
    M. Mazzitelli, E. Raffetti, L. Cosco, R. Marino, A. Mastroianni, N. Serrao, G. Apuzzo, G. Berardelli, J. Carioti, D. Teti, S. Nisticò, L. Surace, G. Foti, C. Torti
      P 98 - Late presentation and six months survival in a cohort of HIV+ subjects diagnosed across the last years in Catania
    A. Pampaloni, M.E. Locatelli, A. Marino, D. Scuderi, M. Maresca, L. Vinci, R. Fontana del Vecchio, R. Bruno, M. Gussio, F. Palermo, B. Cacopardo, B.M. Celesia
      P 99 - Therapy switch in an HIV-infected female cohort: the therapy adherence issue and the ADR risk
    G. Piazza, L. Appolloni, S. Vitale, I. Martens, J. Baldi, M. Morotti, L. Calza, C. Puggioli
      P 100 - Molecular epidemiology of HIV-2 infected migrant in asylum seeker centre
    E. Cella, S. Vita, G. Ceccarelli, M. Fogolari, V. Scolamacchia, G. d’Ettorre, V. Vullo, S. Angeletti, M. Ciccozzi
      P 101 - HIV-1 Subtypes and Circulating Recombinant Forms (CRFs) and blood donation NAT screening test: experience of LIGURIA Region
    G. Ubezio, A. Di Biagio, M. Setti, N. Nigro, A. Marghero, G. Barisione, M.C. De Luigi, P. Strada, B. Bruzzone
      P 102 - Foreign women under 49 years: a high risk group for HIV infection. A single center study in Brescia, Northern Italy
    I. Izzo, A. Celotti, B. Saccani, M. Properzi, E. Quiros-Roldan, A. Ferraresi, M.C. Pezzoli, R. Allegri, F. Castelnuovo, F. Castelli
      P 103 - Direct distribution anti-HIV drugs through the Edotto system: appropriateness, traceability and innovation
    F. Digiuseppe, L. D'Aprile
      P 104 - Epidemiological and clinical characteristics of newly diagnosed HIV infected patients: a single center study in Northern Italy
    I. Izzo, M. Properzi, A. Celotti, B. Saccani, E. Focà, E. Van Hauwermeiren, M.A. Forleo, I. El-Hamad, F. Castelnuovo, F. Castelli
      HIV cascade and retention in care
      P 105 - Epidemiological and clinical characteristics of HIV-infected patients lost to follow up (LTFU) and re-engaged in care: a single-cohort observational study in Northern Italy
    A. Comelli, I. Izzo, E. Quiros-Roldan, F. Castelnuovo, G. Paraninfo, A. Ferraresi, F. Invernici, G. Zambolin, F. Castelli
      P 106 - Retention in care of HIV-positive patients from 2005 to 2014: comparison between Italian and non Italian patients
    C. Gabrielli, E. Schiaroli, G. De Socio, C. Papalini, M. B. Pasticci, F. Baldelli, D. Francisci
      HIV Prevention
      P 107 - Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis: a safe option
    A. Franco, L. Aprea, N. Papa, T. Pizzella, F. Simioli, E. Manzillo
      P 108 - Project Schools, "Anlaids Lazio meets the students": an in/formative school prevention campaign on HIV/AIDS/STI, in cooperation with the National Institute for infectious diseases Spallanzani, to promote safe behaviors and a mindful sexuality in the Lazio Region.
    R. Galipò, E. Farinola, A. Ferraroni, P. Ferri, F. Maroso, S. Ondedei, N. Orchi, A. Palummieri, A. Pulimeno
      P 109 - PrEP awareness and willingness in Italy, a one-month cross sectional study in a free access outpatient clinic
    A. Santoro, G. Guaraldi, G. Campagna, A. Bianchi, N. Riva, I. Franconi, A. Bonazza, A. Raimondi, C. Rogati, C. Ciusa, M. Tutone, C. Mussini
      P 110 - HIV seroconversion after stopping TDF-based treatment for HBV
    B. Tazza, L. Badia, V. Guardigni, G. Verucchi, P. Viale
      P 111 - Unconsistent use of condom in heterosexual HIV-serodiscordant couples from Southeastern Italy as revealed by the detection of Y chromosomal DNA in vaginal swabs
    F. Zoboli, M. Di Stefano, M. Fasano, S.R. Bruno, T.A. Santantonio, J.R. Fiore
      HIV clinical diagnostics
      P 112 - Going towards undetectable: preliminary results
    B. Bruzzone, M. Setti, A. Di Biagio, R. Barresi, N. Nigro, A. Torretta, G. Guarona, P. Strada, G. Ubezio
      P 113 - Evaluation of the rapid HIV-1 RNA quantification Xpert HIV-1 Viral load assay: comparison with the COBAS AmpliPrep/COBAS TaqMan HIV test
    T. Allice, M.G. Milia, E. Burdino, G. Gregori, T. Ruggiero, M. Malta, E. Scuccimarra, P. Tremante, V. Ghisetti
      HIV Immunology
      P 114 - APOBEC3G/3A expression in HIV-1-infected individuals following initiation of antiretroviral therapy containing cenicriviroc or efavirenz
    D.A. Covino, C. Purificato, L. Catapano, C.M. Galluzzo, M.C. Gauzzi, S. Vella, E. Lefebvre, M. Andreotti, L. Fantuzzi
      P 115 - Modulation of the Natural Killer Cell compartment during DAAs treatment in Interferon-naïve HCV patients: the impact of the type of DAA
    L.A. Nicolini, S. Dettori, F. Bozzano, A. Di Biagio, A. De Maria
      P 116 - Peripheral loss of regulatory T cells and polyautoimmunity in a HIV-infected patient
    E. Quiros-Roldan, A. Ferraresi, M. Properzi, A. Bonito, A. Celotti, M.C. Pezzoli, R. Allegri, F. Castelnuovo, E. Focà, I. Izzo, F. Castelli
      P 117 - In HIV primary infection, early cART reduced gd T cell activation but failed to restore their polyfunctionality
    R. Casetti, A. Sacchi, V. Bordoni, E. Cimini, C. Pinnetti, R. Libertone, A. Ammassari, A. Antinori, C. Agrati
      P 118 - Evaluation of myeloid cells, classical, intermediate and non-classical monocytes, T-cell activation markers in virologically suppressed treated patients with DRV-based regimen
    S. Savinelli, S. Vita, C. Mascia, L. Celani, L. Bianchi, M. Lichtner, G. d’Ettorre, V. Vullo. C.M. Mastroianni
      P 119 - Association of inflammation and coagulation markers with clinical, virological or immunological progression of HIV-1 Infection in adult patients naïve to antiretroviral therapy and with a CD4+ T lymphocyte count above 500 cells/MCL
    L. Calza, V. Colangeli, M. Borderi, R. Manfredi, S. Coladonato, B. Tazza, I. Bon, M.C. Re, P. Viale
      P 120 - HIV-1 and host restriction factors: relationship between viral reservoir and RFs expression levels
    V. D'Urbano, S. Longo, E. De Crignis, A. Bertoldi, G. Musumeci, I. Bon, L. Calza, G. Gallinella, M.C. Re
      Vaccines and immune-based therapies
      P 121 - Vaccine usage extent in people living with HIV: a snapshot from a single center cohort
    N. de Gennaro, A. Procopio, C. Santoro, C. Fabrizio, D.F. Bavaro, N. Ladisa, S. Lo Caputo, L. Monno, A. Saracino, G. Angarano
      HIV Pathogenesis
      P 122 - Impact of ART on dynamics of growth factors and cytokines in primary HIV infection
    V. Bordoni, A. Sacchi, R. Casetti, E. Cimini, C. Pinnetti, A. Mondi, A. Ammassari, A. Antinori, C. Agrati
      P 123 - MicroRNA profile and CD4/CD8 ratio recovery after antiretroviral therapy
    A. Gabrieli, L. Dioni, C. Favero, M. Tarkowski, E. Gervasi, S. Limonta, M. Galli, V. Bollati, A. Riva
      HIV Virology
      P 124 - No impact of minor accessory mutations to Integrase strand transfer inhibitors (InSTI) on cART effectiveness after 24 weeks of follow-up: a longitudinal single-cohort study
    A. Celotti, M. Properzi, M. De Francesco, F. Gargiulo, I. Izzo, E. Quiros-Roldan, F. Castelnuovo, A. Bonito, A. Ferraresi, M.C. Pezzoli, A. Caruso, F. Castelli, E. Focà
      P 125 - Epidemiological analysis of primary resistance to Integrase strand –transfer inhibitors in real life setting from January 2016 to December 2017 in “D. Cotugno” Hospital, Naples (Italy)
    S. Mascolo, A. Raddi, M. Sardo, V. Sangiovanni, L. Atripaldi, N. Cuomo
      P 126 - NK cell-mediated lysis of CD4+ T lymphocytes harboring reactivated HIV-1
    M.G. Desimio, E. Giuliani, M. Doria
      P 127 - Role of low-level viremia during chemotherapy for non-hodgkin lymphoma
    G. Bozzi, I. De Benedetto, L. Verga, S. Malandrin, V. Micheli, M. Mena, E. Doni, D. Dalu, C. Fasola, E. Colella, A. Muscatello, C. Gambacorti-Passerini, A. Gori, A. Bandera for the Musthal study group
      P 128 - Apoptotic effects in macrophages infected by CXCR4- but not by CCR5-viruses, caused by the involvement of HIV-1 coreceptors
    A. Borrajo, A. Ranazzi, M.C. Bellocchi, M. Pollicita, V. Svicher, C.F. Perno, S. Aquaro
      Neuropathogenesis and neurologic complications
      P 129 - Mini-Addenbrooke’s Cognitive Examination test for HIV-Associated Neurocognitive Disorders
    M. Trunfio, M. Milesi, D. Vai, C. Montrucchio, C. Alcantarini, M.C. Tettoni, G. Orofino, S. Audagnotto, D. Imperiale, S. Bonora, G. Di Perri, A. Calcagno
      Pediatric, adolescent, maternal, fetal aspects
      P 130 - Viral and Immunological Profile of HIV-1 chronically infected children under cART with or without persistent suppression of HIV-1 plasmaviremia
    A. Dalzini, G. Ballin, F. Carmona, R. Freguja, M.R. Petrara, M. Zanchetta, O. Rampon, C. Giaquinto, A. de Rossi
      P 131 - Rilpivirine during pregnancy: is it associated with preterm delivery?
    F. Peruzzu, M.J. Lopes, M. Caixeiro, D. Trigo, J. Batista, B.F. de Lima, G. Madeddu, S. Babudieri, P. Pacheco
      P 132 - Adherence to antiretroviral therapy in HIV+ Adolescents: an open issue for multidisciplinary team
    G. Orofino, M. Guastavigna, M. Farenga, D. Penoncelli, S. Carosella, S. Lupo, G. Cinnirella, C. Gabiano, P. Caramello
      P 133 - Effects of universal access to ART on MTC transmission and maternal health in West Cameroon
    A.M. Doro Altan, L. Palombi, F. Ciccacci, F. Taafo, J. Castro Forns, S. Orlando, S. Mancinelli, C. Marazzi
      Pharmacology, pharmacogenomics and drug interactions
      P 134 - How relevant are drug-drug interactions between boosted antiretroviral -based regimens and calcium channel blockers in real life?
    D. Cattaneo, T. Formenti, N. Astuti, P. Meraviglia, A. Ridolfo, C. Gervasoni
      P 135 - A pharmacogenetic study in ritonavir treated patients: hematological and cardiovascular disease risk analysis
    J. Cusato, A. Calcagno, S. Allegra, M. Antonucci, L. Marinaro, A. De Nicolo’, S. Bonora, G. Di Perri, A. D’Avolio
      P 136 - Factors influencing sofosbuvir intracellular concentrations at one month of therapy
    J. Cusato, A. De Nicolò, L. Boglione, G. Caviglia, M. Sciandra, S. Mornese Pinna, A. Ciancio, G. Troshina, A. Smedile, C. Carcieri, G. Cariti, G. Saracco, G. Di Perri, A. D’Avolio
      P 137 - Use of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in a HIV-positive woman during pregnancy
    C. Alcantarini, M.Tettoni, L.Trentini, C. Costa, C. Montrucchio, A.Trentalange, N. Forni, A. Barco, G. Masuelli, C. Scolfaro, V. Avataneo, A. De Nicolò, A. D'Avolio, A. Calcagno, S. Bonora, G. Di Perri
      P 138 - Myocardial infarction and other adverse drug reaction among antiretroviral treatment in HIV positive patients
    M. De Fina
      Programmatic issues, implementation of diagnosis and care
      P 139 - Access to anti-HCV treatment with DAAs in the migrant population in Italy: data from the Piter cohort
    A. Saracino, D.F. Bavaro, S. Rosato, A. Giorgini, R. Corsini, E. Castelli, M. Vinci , F. Baragli, E. Biliotti, A. Orlandini, M. Monti, A. Zanetto, C. Baiguera, G. Morsica, A. Soria, S. Bruno, A. Ciancio, V. Donati, V. Calvaruso, M.G. Quarant a on behalf of PITER collaborating group
      P 140 - The motivation analysis of the HIV-infected patients to spontaneous access to the hospital psychotherapy service in San Raffaele Hospital
    M.M. Ratti, E. Sangiovanni, G.B. Delli Zotti, L. Sarno
      P 141 - Free to live well with HIV in prison
    A. Battistella, S. Dell’Isola, S. Babudieri, G. Starnini, M. Errico, C. Frontini, A. Borrelli, F. Perocco, M. Cascio, M. Formisano, FLEW group* *Collaborators: E. Rastrelli, A. Ialungo, S. Marcellini, M. Scuderi, M. Merlino, S. Carbonara, L. D'Argenio, T. Prestileo, F. Di Lorenzo, E. Pontali, L. Butini, G. Korb
      P 142 - Doctor Apollo: a digital health tool to improve management and wellbeing of people living with HIV
    S. Vita, R. Marocco, I. Pozzetto, G. Morlino, E. Vigilante, L. Fondaco, B. Kertusha, G. Colazingari, V. Mercurio, V. Vullo, C.M. Mastroianni, M. Lichtner
      P 143 - Capillary free HIV testing at voluntary and counseling PEG Checkpoint: report of tests performed in 2016-2017
    S. Cardaci, E. Albertini, C. Sfara, C. Papalini, V. Scaglione, E. Riguccini, M. Nofri, F. Paciosi, A. Gidari, C. Gabrielli, G. Angeli, D. Rosignoli, P. Diana, L. Ciaccarini, M.G. Gaggini, F. Baldelli
      P 144 - BLQ Checkpoint: characteristics of users in the first 30 months of activity
    S. Mattioli, M. Bonanni, C. Degli Esposti, C. Franchini, P. Gorgoni, P. Pieralli, P. Tomasi, G.M. Corbelli
      P 145 - Financial costs related to antiretroviral treatment switch (Studio Costi attribUibili alla moDIfica di una terapia antiretrovirale-SCUDI). Preliminary analysis
    G. Cenderello, B. Giannini, M. Giacomini, R. Ungaro, N. Riccardi, D. Fiorellino, G. Cassola, A. Di Biagio
      P 146 - Psychological assessment of HIV-infected patients in need of a psychoterapeutic treatment: psychopathological related characteristics
    G.B. Delli Zotti, M.M. Ratti, E. Sangiovanni, L. Sarno
      Social and behavioural science, marginalized groups, community aspects and community surveys
      P 147 - Educational and training initiatives increase participants’ competence about HIV
    L. Rancilio, C. Neglia and the AIDS network of Caritas Italiana
      P 148 - Alcohol use disorder in HIV infected people
    M. Scarzella, G. Mozzone, S. Rusconi
      P 149 - Alice & frames - Alice e Cornici
    A. Infante
      P 150 - “What about AIDS?” Health education targeted at student population
    S. Antonelli, P. Roselli, P. Mancino, M.P. Sciotti, M.R. Ferrone, M. Marra, M. Grasso, S. Del Borrello, C. Di Giambattista
      P 151 - Should we improve student’s knowledge about STIs? Preliminary results from a pilot project in a Secondary High School in Sassari, Italy
    N. Ronzoni, V. Fiore, P. Bagella, G. Caruana, F. Peruzzu, F. Mori Ubaldini, G. Flore, V. Nardi, A.G. Pintus, S. Babudieri, G. Madeddu
      P 152 - Testing MSM in cruising venues: perception of the risk of infection
    D. Zagato, A. Bianchi, A. Costantino, F.M. Esposito, G. Fissore, S. Lolli, M. Manfredini, V. Nicotera, D. Pennisi, A. Pezzotti, M. Pierini, F. Rossi, R. Rossotti, J. G. Scalisi, P. Testoni, P. Vinti, M. Zoia, M. Cernuschi
      P 153 - Serodiscordant partner: exception or normality?
    M. Zetti, A. Bianchi, M. Cernuschi
      P 154 - Behaviors and knowledge on HIV and sexually transmitted infections (STIs) among blood donors and people sensitive to donation
    V. Regine, L. Pugliese, A. Argentoni, V. Saturni, F. Marchionni, A. Simonetti, B. Suligoi
      P 155 - The self-help group as a resource in better dealing with HIV infection: 10 years of experience in Arcobaleno AIDS
    S. Patrucco, A. Siliato, P. Gusmeroli, P. Altini, G. Orofino
      P 156 - #SalutediGruppo: using the social network Facebook as virtual motivators to physical exercise and wellness for persons living with HIV
    F. Turrini, M. Bonato, L. Reiss, L. Passeri, L. Galli, C. Vitobello, A. Giordani, S. Giuliani, A. Meloni, A. La Torre, A. Lazzarin, G. Merati, P. Cinque
      P 157 - A desk for a material assistance, psychological support and work orientation for HIV-positive - LABORES
    S. Negri, M. Bagnato, B. Bongini, C. Falanga
      Translational sciences
      P 158 - The role of HIV protease inhibitors on mesenchymal stem cells in vitro differentiation
    S. De Rose, A. Cazzaniga, V. Romeo, J.A.M. Maier, S. Rusconi
      P 159 - Analyses of protective genetic polymorphisms in HIV-infected cART treated patients
    E.M. Lori, A. Cozzi-Lepri, M. Biasin, V. Mercurio, S. Lo Caputo, F. Castelli, A. Castagna, A. Gori, G. Marchetti, C. Venditti, M. Clerici, A. d’Arminio Monforte
      Any other issue
      P 160 - Prevalence, risk factors and subtypes of Blastocystis spp. in HIV infected patients in Italy
    L. Fontanelli Sulekova, M. Maiorano, S. Gabrielli, G. Iaiani, C. Fimiani, M. De Angelis, E. Biliotti, R. Esvan, D. Palazzo, M. Spaziante, M. Rivano, Capparuccia, G. Taliani
      P 161 - Vaccination coverage in HIV positive adult patients in ASL 1 Imperia
    I. De Macina, R. Furnari, D. Zollo, M. Duberti, A. Riccio, C. Dentone, M. Mela
×
Chiudi
×
Chiudi
×
Chiudi